Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03172208 · ClinicalTrials.gov registry record · Phase 1
Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.
A Phase 1 study of Healthy Volunteers, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03172208: Completed Phase 1 study of Healthy Volunteers, sponsored by Ablynx, a Sanofi company.
NCT03172208 is a Phase 1 study of Healthy Volunteers that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 60 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03172208, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary objective: To assess the safety and tolerability of single ascending intravenous (i.v.) doses, a single subcutaneous (s.c.) dose of caplacizumab (Part I), and multiple s.c. doses of caplacizumab (Part II) in Japanese subjects. Secondary objectives: * To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles (total vWF:Ag concentration levels \[vWF:Ag\], coagulation factor VIII \[FVIII:C\], and ristocetin cofactor activity \[RICO\]) after single i.v. or s.c. administration of caplacizumab in Japanese and White subjects. * To evaluate the immunogenicity of caplacizumab (anti-drug antibodies \[ADA\]) in Japanese subjects.
Conditions Studied
Interventions
- BIOLOGICAL Caplacizumab Dose 1 iv (single-dose)
- BIOLOGICAL Caplacizumab Dose 2 iv (single-dose)
- BIOLOGICAL Caplacizumab Dose 2 sc (single-dose)
- BIOLOGICAL Caplacizumab Dose 2 sc (multiple-dose)
- OTHER Placebo iv (single-dose)
Study Locations (1)
California
- Investigator Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2017-10-19 |
| Phase | Phase 1 |
What the finished NCT03172208 record still lists
NCT03172208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Caplacizumab Dose 1 iv (single-dose) is the first listed.
NCT03172208 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03172208 about?
NCT03172208 is a clinical study titled "Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.". Primary objective: To assess the safety and tolerability of single ascending intravenous (i.v.) doses, a single subcutaneous (s.c.) dose of caplacizumab (Part I), and multiple s.c. doses of caplacizumab (Part II) in Japanese subjects. Secondary objectives: * To compare the pharmacokinetic (PK) an...
What is the current status of trial NCT03172208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-06-05. Estimated completion is 2017-10-19.
What conditions does trial NCT03172208 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT03172208?
The interventions under investigation include: Caplacizumab Dose 1 iv (single-dose) (BIOLOGICAL), Caplacizumab Dose 2 iv (single-dose) (BIOLOGICAL), Caplacizumab Dose 2 sc (single-dose) (BIOLOGICAL), Caplacizumab Dose 2 sc (multiple-dose) (BIOLOGICAL), Placebo iv (single-dose) (OTHER).
Who is sponsoring clinical trial NCT03172208?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03172208 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03172208's enrollment target sits among peer trials
60 109th of 283 higher than 163 of 283 other Healthy Volunteers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI